These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 19837916)

  • 1. RAS mutations are the predominant molecular alteration in poorly differentiated thyroid carcinomas and bear prognostic impact.
    Volante M; Rapa I; Gandhi M; Bussolati G; Giachino D; Papotti M; Nikiforov YE
    J Clin Endocrinol Metab; 2009 Dec; 94(12):4735-41. PubMed ID: 19837916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genotyping of an Italian papillary thyroid carcinoma cohort revealed high prevalence of BRAF mutations, absence of RAS mutations and allowed the detection of a new mutation of BRAF oncoprotein (BRAF(V599lns)).
    Carta C; Moretti S; Passeri L; Barbi F; Avenia N; Cavaliere A; Monacelli M; Macchiarulo A; Santeusanio F; Tartaglia M; Puxeddu E
    Clin Endocrinol (Oxf); 2006 Jan; 64(1):105-9. PubMed ID: 16402937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PAX8-PPARgamma rearrangement is frequently detected in the follicular variant of papillary thyroid carcinoma.
    Castro P; Rebocho AP; Soares RJ; Magalhães J; Roque L; Trovisco V; Vieira de Castro I; Cardoso-de-Oliveira M; Fonseca E; Soares P; Sobrinho-Simões M
    J Clin Endocrinol Metab; 2006 Jan; 91(1):213-20. PubMed ID: 16219715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive survey of HRAS, KRAS, and NRAS mutations in proliferative thyroid lesions from an ethnically diverse population.
    Schulten HJ; Salama S; Al-Ahmadi A; Al-Mansouri Z; Mirza Z; Al-Ghamdi K; Al-Hamour OA; Huwait E; Gari M; Al-Qahtani MH; Al-Maghrabi J
    Anticancer Res; 2013 Nov; 33(11):4779-84. PubMed ID: 24222113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular genetic study comparing follicular variant versus classic papillary thyroid carcinomas: association of N-ras mutation in codon 61 with follicular variant.
    Di Cristofaro J; Marcy M; Vasko V; Sebag F; Fakhry N; Wynford-Thomas D; De Micco C
    Hum Pathol; 2006 Jul; 37(7):824-30. PubMed ID: 16784981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aneuploidy and RAS mutations are mutually exclusive events in the development of well-differentiated thyroid follicular tumours.
    Banito A; Pinto AE; Espadinha C; Marques AR; Leite V
    Clin Endocrinol (Oxf); 2007 Nov; 67(5):706-11. PubMed ID: 17651453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of ras mutations.
    Zhu Z; Gandhi M; Nikiforova MN; Fischer AH; Nikiforov YE
    Am J Clin Pathol; 2003 Jul; 120(1):71-7. PubMed ID: 12866375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. N-ras mutation in poorly differentiated thyroid carcinomas: correlation with bone metastases and inverse correlation to thyroglobulin expression.
    Basolo F; Pisaturo F; Pollina LE; Fontanini G; Elisei R; Molinaro E; Iacconi P; Miccoli P; Pacini F
    Thyroid; 2000 Jan; 10(1):19-23. PubMed ID: 10691309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
    Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
    Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutation profile of differentiated thyroid tumours in an Australian urban population.
    Mond M; Alexiadis M; Fuller PJ; Gilfillan C
    Intern Med J; 2014 Aug; 44(8):727-34. PubMed ID: 24862939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular genotyping of papillary thyroid carcinoma follicular variant according to its histological subtypes (encapsulated vs infiltrative) reveals distinct BRAF and RAS mutation patterns.
    Rivera M; Ricarte-Filho J; Knauf J; Shaha A; Tuttle M; Fagin JA; Ghossein RA
    Mod Pathol; 2010 Sep; 23(9):1191-200. PubMed ID: 20526288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer.
    Garcia-Rostan G; Zhao H; Camp RL; Pollan M; Herrero A; Pardo J; Wu R; Carcangiu ML; Costa J; Tallini G
    J Clin Oncol; 2003 Sep; 21(17):3226-35. PubMed ID: 12947056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma.
    Nikiforova MN; Lynch RA; Biddinger PW; Alexander EK; Dorn GW; Tallini G; Kroll TG; Nikiforov YE
    J Clin Endocrinol Metab; 2003 May; 88(5):2318-26. PubMed ID: 12727991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic alterations involved in the transition from well-differentiated to poorly differentiated and anaplastic thyroid carcinomas.
    Nikiforov YE
    Endocr Pathol; 2004; 15(4):319-27. PubMed ID: 15681856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High prevalence of RAS mutations in RET-negative sporadic medullary thyroid carcinomas.
    Moura MM; Cavaco BM; Pinto AE; Leite V
    J Clin Endocrinol Metab; 2011 May; 96(5):E863-8. PubMed ID: 21325462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma.
    Costa AM; Herrero A; Fresno MF; Heymann J; Alvarez JA; Cameselle-Teijeiro J; García-Rostán G
    Clin Endocrinol (Oxf); 2008 Apr; 68(4):618-34. PubMed ID: 18070147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis.
    Giordano TJ; Kuick R; Thomas DG; Misek DE; Vinco M; Sanders D; Zhu Z; Ciampi R; Roh M; Shedden K; Gauger P; Doherty G; Thompson NW; Hanash S; Koenig RJ; Nikiforov YE
    Oncogene; 2005 Oct; 24(44):6646-56. PubMed ID: 16007166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic Alterations in Differentiated Thyroid Cancer Patients with Acromegaly.
    Aydin K; Aydin C; Dagdelen S; Tezel GG; Erbas T
    Exp Clin Endocrinol Diabetes; 2016 Mar; 124(3):198-202. PubMed ID: 26575115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular testing for oncogenic gene mutations in thyroid lesions: a case-control validation study in 413 postsurgical specimens.
    Giordano TJ; Beaudenon-Huibregtse S; Shinde R; Langfield L; Vinco M; Laosinchai-Wolf W; Labourier E
    Hum Pathol; 2014 Jul; 45(7):1339-47. PubMed ID: 24830619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic alterations in the RAS/RAF/mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways in the follicular variant of papillary thyroid carcinoma.
    Santarpia L; Myers JN; Sherman SI; Trimarchi F; Clayman GL; El-Naggar AK
    Cancer; 2010 Jun; 116(12):2974-83. PubMed ID: 20564403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.